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Factors modifying stress from adverse effects
of immunosuppressive medication in kidney
transplant recipients
Successful kidney transplantation requires eﬀect-
ive immunosuppression. However, immunosup-
pressive drugs are well-known for their wide range
of adverse eﬀects; this puts them into one of the
top positions in the rankings of various stressors
(1–3).
Among the most signiﬁcant adverse eﬀects are
infections, because of their graft and life-threatening
Rosenberger J, Geckova AM, van Dijk JP, Roland R, van den Heuvel
WJA, Groothoﬀ JW. Factors modifying stress from adverse eﬀects of
immunosuppressive medication in kidney transplant recipients.
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Abstract: Introduction: The adverse eﬀects of immunosuppression appear
in the majority of patients with a negative impact on morbidity, mortality
and quality of life. The group of adverse symptoms manifested as changes
in appearance, mood and energy are often more stressful than serious
metabolic changes because of their direct negative inﬂuence on patients
well-being. The aim of this study is to explore the adverse symptoms of
immunosuppressive medication which are the most stressful for transplan-
ted patients, and which are the modifying factors.
Patients and methods: A total of 157 adult kidney transplant recipients
from two transplant centres in Slovakia with a functioning graft trans-
planted <7 yr ago were examined. Patients participated in an interview
focusing on stress from adverse eﬀects, and their education and
social support. Medical records were searched for information about
immunosuppression protocols, dialysis treatment before transplantation,
type of received organ and period after transplantation. The eﬀect of the
selected variables on the total score for stress from adverse eﬀects was tested
using ANOVA. The eﬀect of the selected factors on stress from each single
adverse eﬀect was explored using t-test and ANOVA.
Results: The most stressful symptoms were pain, weakness, weight gain,
facial changes, depression and anxiety. The mean value of the total score
for stress from adverse eﬀects was 8.03 ± 6.53 (minimum 0, maximum 30,
range: 0–64), indicating low stress. Women and patients with lower
education signiﬁcantly more often felt the adverse eﬀects of immunosup-
pression as stressful (p < 0.001 and p < 0.05, respectively). Age, social
support, dialysis modality before transplantation, time from transplanta-
tion and type of immunosuppressive treatment did not aﬀect the total score
for stress from adverse eﬀects. However, variables that were not signiﬁcant
in the overall score reached signiﬁcance in some symptoms.
Conclusions: Women and patients with lower education signiﬁcantly
more often felt the adverse eﬀects of immunosuppression as stressful; in a
more detailed analysis the use of new drugs was connected with less stress in
some symptoms. The use of these drugs can improve life quality for
transplant recipients, decrease non-compliance, and thus prevent graft loss.
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potential (4). New immunosuppressive drugs in
particular are very eﬀective in preventing acute and
chronic kidney damage, but they also increase the
potential for various infections (5). Oncological
adverse eﬀects are very menacing, and the risk of
acquiring cancer is three- to ﬁve-fold higher in
transplanted patients when compared with the
standard population (6, 7). The most common
adverse eﬀects are hypertension and metabolic
changes (e.g. diabetes, hyperuricaemia, hypercho-
lesterolaemia), and their importance lies in their
negative inﬂuence on long-term cardiovascular
morbidity and mortality (8, 9).
Besides these well-known eﬀects another group
of adverse symptoms causes distress to transplan-
ted patients. These emerge as the results of the
complex mechanism of immunosuppressive treat-
ment and they become manifest as changes of
appearance, mood and energy (10–12). For
patients, these symptoms are often more stressful
than serious metabolic changes because of the
direct negative inﬂuence on their well-being
(12, 13). Deterioration of well-being may even
cause non-compliant behaviour (14, 15), which is
one of the leading causes of late acute rejection and
graft loss (16–18).
Traditionally, a number of side-eﬀects are linked
to steroids. They are responsible for weight gain,
weakness, negative psychological symptoms, oede-
mas and skin changes (19, 20). Increased growth of
gum and hair is usually connected with calcineurin
inhibitors.
The adverse eﬀects of immunosuppression
appear in the majority of patients and they have
a negative impact on morbidity and mortality as
well as on quality of life. This makes follow-up
necessary (21).
The aim of this study was to explore which non-
infectious, non-oncological adverse symptoms of
immunosuppressive medication are the most stress-
ful for a transplanted patient. It also focuses on the
contribution of various socio-demographic, med-
ical factors and social support to the development
of stress from these adverse eﬀects. Finally, the
study explores the role of these factors aﬀecting
stress from each separate adverse eﬀect.
Patients and methods
Patients
Data collection took place from September 2002 to
September 2003 in two transplant centres in
Slovakia (Kosˇice and Bratislava). Adult kidney
transplant recipients with a functioning graft
transplanted <7 yr ago were informed about the
study by their nephrologist. Of 167 informed
patients, 157 agreed to participate. The only
exclusion criterion was the inability to answer
questions during the interview because of severe
dementia or mental retardation. All patients signed
an informed consent before the interview. The
study was approved by the local ethical committee.
Interview
Each patient participated in an interview with a
trained interviewer focusing on the stress from
adverse eﬀects of immunosuppression. Based on a
literature search (19, 20, 22, 23) and the results of a
small pilot study, 16 various adverse symptoms of
immunosuppression were identiﬁed. Stress from
each of these adverse eﬀects of immunosuppression
was measured with a 5-point scale (0, no stress;
1, low stress; 2, moderate stress; 3, high stress; 4,
very high stress). For each patient, a total score of
all adverse eﬀects was calculated as the sum of
scores in all items (possible range: 0–64).
Education was categorized as elementary, sec-
ondary or university. Satisfaction with social
support was also measured using a 5-point scale
(1, excellent; 2, good; 3, fair; 4, poor; 5, bad).
However, after preliminary results this variable
was trichotomized by merging three last categories
(1, excellent; 2, good; 3, bad).
Medical records
Patient medical records were searched for infor-
mation about their immunosuppressive regimen,
dialysis treatment before transplantation (haemo-
dialysis, peritoneal dialysis or both methods), type
of received organ (cadaveric, living) and the
moment of transplantation.
Statistics
Statistical analysis was performed using SPSS 10.1.0
(SPSS Inc., Chicago, IL, USA). The eﬀect of
selected socio-demographic variables (age, gender,
education), social support, dialysis modality before
transplantation, time from transplantation and
immunosuppressive regimen on the total score for
stress from adverse eﬀects was tested using ANO-
VA. Two models were explored: one model inclu-
ding the main eﬀects and all two-way interactions
and one without interactions. The eﬀect of selected
factors on stress from each single adverse eﬀect
was explored using a t-test for dichotomous (age,
gender, immunosuppression treatment) and one-
way ANOVA for trichotomous (education, social
support, time from transplantation) variables.
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Post-hoc tests were performed for variables that
were found to be signiﬁcant in ANOVA.
Results
The sample consisted mainly of middle-aged
cadaveric kidney recipients with secondary educa-
tion and haemodialysis treatment before trans-
plantation. The majority of patients declared their
social support as excellent or good, and the mean
score for social support was 1.66 ± 0.8 (range:
1–3), indicating a supportive environment. Nearly
all patients had their immunosuppressive protocol
based on cyclosporin (CsA), and the predominant
regimen consisted of prednison (P), CsA and
mycofenolate mofetil (MMF). According to their
immunosuppressive regimens patients were consid-
ered to be steroid-treated (75.8%), CsA-treated
(95.4%), mycofenolate-treated (59.5%), azathio-
prin (Aza)-treated (17.6%) and tacrolimus (Tac)-
treated (4.6%). A more detailed description of the
patient sample is shown in Table 1.
Results of stress from each single adverse eﬀect
are presented in Table 2 in descending order
according to stressfulness. The most stressful
symptoms were pain, malaise, muscle weakness
and major physical cosmetic changes such as
weight gain and facial changes, followed by
psychological symptoms (depression and anxiety).
The total score for stress from all items varied
between 0 and 30 (possible range: 0–64), and the
mean value for the whole sample was 8.03 ± 6.53,
indicating low mean stress.
The eﬀects of gender, age, education, social
support, modality of dialysis before transplanta-
tion, immunosuppression protocol and time from
transplantation on stress from adverse eﬀects
of immunosuppression were analysed (Table 3).
None of the explored two-way interactions were
signiﬁcant, so only the model including main eﬀect
without interactions is described. Women com-
pared with men (p < 0.001), and patients with
lower education compared to those with university
education (p < 0.05), more often felt the adverse
eﬀects of immunosuppression as stressful. Age,
social support, dialysis modality before transplan-
tation, time from transplantation and modality of
immunosuppressive treatment did not aﬀect the
total score for stress from adverse eﬀects.
On the contrary, the main eﬀect of the selected
variables on the score for stress is not visible in
each symptom. In addition, variables that were not
signiﬁcant in the overall score (age, social support,
modality of dialysis, time from transplantation)
reached signiﬁcance in some symptoms. These
results are presented in Table 4. Women felt pain,
Table 1. Basic description of patient sample and treatment characteristics
(n ¼ 157)




Age (yr) 47.7 ± 11.7 (18.3–74)











Living donor 4 2.6
Cadaveric donor 151 97.4
Dialysis before transplantation
Haemodialysis 119 79.9
Peritoneal dialysis 19 12.8
Both 11 7.3
Time from transplantation 37.7 ± 27.3 months (3–144)
£ 3 months 24 15.5
4–36 months 56 36.1
>36 months 75 48.4
Immunosuppressive regimen
CsA 11 7.1
P + CsA 24 15.6
CsA + Aza 6 3.9
CsA + MMF 20 13.0
P + CsA + Aza 21 13.6
P + CsA + MMF 65 42.2
P + Tac + MMF 7 4.5
P, prednison; CsA, cyclosporin A; Aza, azathioprin; MMF, mycofenolate mofetil;
Tac, tacrolimus.
Table 2. Scores for stress from adverse effects of immunosuppression
Symptom Mean ± SD (range)
Pain 0.90 ± 1.05
Malaise 0.87 ± 1.01
Muscle weakness 0.79 ± 0.96
Weight gain 0.77 ± 1.00
Facial changes 0.66 ± 0.94
Depression 0.58 ± 0.94
Fear, anxiety 0.58 ± 0.95
Sleep disorders 0.49 ± 0.84
Gingival hyperplasia 0.43 ± 0.89
Skin lesions 0.38 ± 0.83
Leg oedemas 0.38 ± 0.80
Hair loss 0.34 ± 0.82
Sexual dysfunction 0.33 ± 0.81
Facial oedemas 0.22 ± 0.52
Diarrhoea 0.18 ± 0.56
Fragile skin 0.12 ± 0.47
Mean total score for stress from all items 8.03 ± 6.53 (0–30)
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malaise, weakness and physical cosmetic symptoms
(weight gain, facial changes, oedemas, hair loss) to
be more stressful than men. Younger patients were
more stressed by physical changes (hair loss, facial
changes and gingival hyperplasia) and they repor-
ted less trouble with sleep. Less-educated patients
more often reported depression, anxiety and stress
from leg oedemas and fragile skin. Patients with
poor social support were more troubled by diar-
rhoea. Patients who were on peritoneal dialysis
before transplantation reported more trouble with
gingival hyperplasia. Stress from facial changes
and oedemas was more likely to be present in the
ﬁrst months after transplantation; pain was repor-
ted more frequently in later periods.
One of the important medical factors is immuno-
suppressive medication as it causes adverse eﬀects
that are sources of stress for a patient. However,
immunosuppressive protocols involve several
drugs, so it was impossible to include them in the
analysis we performed. For this reason, the analy-
sis of the eﬀect of separate immunosuppressive
drugs (steroids, CsA, MMF, Aza, Tac) on each
symptom were performed. Surprisingly, the eﬀects
were signiﬁcant only in a few symptoms. When
steroid (P) treatment was present, patients reported
more stress from facial changes. Patients treated
with Aza were more stressed by diarrhoea.
Adversely, usage of MMF was connected with less
stress from pain, malaise, skin lesions and diar-
rhoea. There was no relationship between stress
and treatment with CsA or Tac.
Table 3. Effects of selected factors on total score for stress from adverse
effects of immunosuppression
Factor Mean ± SD p-Value
Gender
Male 6.28 ± 5.51 0.000**
Female 10.46 ± 7.00
Age (yr)
£ 50 8.06 ± 6.62 0.540
>50 7.62 ± 6.22
Education
Elementary 9.96 ± 8.16 0.027*
Secondary 7.89 ± 5.90
University 3.57 ± 3.92
Social support
Excellent 7.51 ± 6.15 0.559
Good 8.31 ± 6.42
Bad 8.06 ± 7.77
Dialysis before transplantation
Haemodialysis 8.00 ± 6.47 0.671
Peritoneal dialysis 7.61 ± 6.48
Both modalities 7.00 ± 6.48
Time from transplantation (month)
£ 3 7.38 ± 5.27 0.555
4–36 6.92 ± 5.87
>36 8.71 ± 7.06
Immunosuppression protocol
CsA 7.60 ± 6.59 0.612
P, CsA 9.61 ± 8.05
CsA, Aza 5.33 ± 4.41
CsA, MMF 6.88 ± 5.35
P, CsA, Aza 9.90 ± 7.03
P, CsA, MMF 7.07 ± 5.99
P, Tac, MMF 8.14 ± 5.58
P, prednison; CsA, cyclosporin A; Aza, azathioprin; MMF, mycofenolate mofetil;
Tac, tacrolimus.
*p £ 0.05; **p £ 0.001.















P CsA MMF Aza Tac
Pain ›*** ns ns ns ns ﬂ* ns ns ﬂ** ns ns
Malaise ›** ns ns ns ns ns ns ns ﬂ* ns ns
Muscle weakness ›** ns ns ns ns ns ns ns ns ns ns
Weight gain ›** ns ns ns ns ns ns ns ns ns ns
Facial changes ›** ›* ns ns ns ›** ›** ns ns ns ns
Depression ns ns ›* ns ns ns ns ns ns ns ns
Fear, anxiety ns ns ›* ns ns ns ns ns ns ns ns
Sleep disorders ns ﬂ*** ns ns ns ns ns ns ns ns ns
Gingival hyperplasia ns ›* ns ns ›* ns ns ns ns ns ns
Skin lesions ns ns ns ns ns ns ns ns ﬂ* ns ns
Leg oedemas ›** ns ›* ns ns ›* ns ns ns ns ns
Hair loss ›* ›* ns ns ns ns ns ns ns ns ns
Sexual dysfunction ns ns ns ns ns ns ns ns ns ns ns
Facial oedemas ›** ns ns ns ns ›* ns ns ns ns ns
Diarrhoea ns ns ns ›*** ns ns ns ns ﬂ* ›** ns
Fragile skin ns ns ›** ns ns ns ns ns ns ns ns
SoS, satisfaction with social support; dialysis, dialysis modality before transplantation; time, time from transplantation; P, prednison; CsA, cyclosporin A; Aza, azathioprin;
MMF, mycofenolate mofetil; Tac, tacrolimus; ns, not significant.
*p £ 0.05; **p £ 0.01; ***p £ 0.001.
›(ﬂ) – variable shows increased (decreased) stress in displayed reference category (in parenthesis below main category).
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Discussion
This study focuses on non-infectious, non-
oncological adverse eﬀects of immunosuppression
which patients themselves are able to identify and
rate. In contrast to Lough et al., de Geest et al.
and Moons et al. (17, 19, 20, 22, 23), we only
measured distress and not frequency of adverse
symptoms. We found that the most stressful
symptoms are pain, weakness, physical changes
and psychological symptoms. In general, these
results are similar to those from earlier studies
(10, 19, 22), but there are some diﬀerences from
other studies (13, 20), which are possibly caused
by predominance of diﬀerent immunosuppression
protocols.
Pain comes at the top of the list of stressors
(10, 19, 22). Our patients mostly report backache
related to osteoporosis and headache. Stress from
pain is gender-speciﬁc with females reporting more
stress than males (19, 22). As osteoporosis pro-
gressively deteriorates with time, pain is reported
with increasing frequency as well. Use of MMF
enables steroid dose reduction and these patients
report less trouble with back pain.
Malaise and muscle weakness are also rated as
strong stressors by our patients. A study by Lough
et al. with immunosuppression after heart trans-
plantation found a high occurrence of fatigue
distress rated as the third item after impotence and
overeating (20). Weakness is diﬀerently perceived
by the two genders. Females are more stressed by
these symptoms than males. These results accord
with the ﬁndings of de Geest et al. (18) and Moons
et al. (19). Their female patients ranked stress from
muscular weakness in ﬁrst place in comparison
with the males, who ranked it in the fourth place
(19, 22, 23). We found a signiﬁcant reduction of
stress from malaise in patients with MMF treat-
ment, probably as a result of lower steroid doses in
these patients.
Major cosmetic defects – weight gain and
facial changes – are also rated as strong stressors
and they disturb signiﬁcantly more women than
men. In addition, distress from facial changes is
more often reported in young patients in com-
parison with the older ones, and in patients in
the early post-transplant period compared with
those in the late post-transplant period. These
diﬀerences are connected with steroid use, which
are more intensive in early post-transplant period
and in young patients (19). Steroid-sparing immu-
nosuppressive regimens, as well as protocols with
early withdrawal of steroids, produce fewer side-
eﬀects and they improve the patient’s well-being
(24, 25).
Patients requiring any renal replacement therap-
ies are well-known for their considerable emotional
diﬃculties (10, 12, 13). It is not surprising therefore
that we found psychological symptoms (depres-
sion, fear, anxiety) strongly represented in our
sample. Most papers report that fear of rejection,
fear of infection, uncertainty about the future and
the possibility of repeated hospitalization are
strong sources of anxiety and depression (1–3, 11,
21, 26). Sutton and Murphy found a signiﬁcant
correlation between stressor scores and coping
scores (26). Our results suggest that there is some
association between education level and psycholo-
gical symptoms. Higher educated persons seem to
develop more coping strategies and so they are less
worried and depressed.
The rest of the assessed symptoms show lesser
importance. Sleep disorders are more common in
older patients, but this pattern is the same in any
population. Hair loss and oedemas are uncommon
symptoms, and they are felt the same way as major
cosmetic defects – they cause stress to more women
and younger people. In addition, oedemas are
found mostly in the early post-transplant period.
Previous research rated impotence and decreased
interest in sex as very stressful for males (12, 13, 19,
20, 22, 23). We were surprised by the low stress-
fulness of sexual dysfunction among our patients,
and we failed to ﬁnd any gender and age diﬀer-
ences. In contrast to our ﬁndings, Breza et al.
reported a very high prevalence of erectile dys-
function (72%) among transplanted Slovak men in
his study (27). We may speculate that sexual
troubles are still a taboo amongst the Slovak
population, and our study did not intensively focus
on this topic, in contrast to the study by Breza
et al. (27).
Surprisingly, our study did not identify the type
of immunosupressive regimen as a signiﬁcant
factor aﬀecting stress from all adverse eﬀects.
Previous research mostly studied protocols based
on steroids, CsA and Aza (8, 13, 16, 19, 20, 22, 23).
In contrast, the majority of patients in our sample
were treated with a combination of CsA, steroids
and MMF. Azathioprin was used only in 17.6% of
patients. Our ﬁndings showed a negative inﬂuence
of steroids leading to stress from facial changes
(e.g. moon face, increased hair growth). This
symptom is stressful for patients in the early
post-transplant period who are on higher steroid
and CsA doses, but after some time, when drugs
are tapered down, the importance of this symptom
decreases. Today, quick steroid tapering as well as
lower CsA levels are allowed due to the use of
MMF and antibodies induction therapy (28). This
leads to lower occurrence of stress from various
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symptoms in mycofenolate-treated patients. As a
result, a well-balanced combination of immuno-
suppressive drugs causes fewer adverse eﬀects and
is superior to regimens used in the past. Tacrolimus
was recently used only for rescue therapy in
Slovakia, so very few patients were recruited into
our study. Unfortunately, our Tac subsample is
too small (4.6%) to show any signiﬁcant diﬀer-
ences. But in the light of some studies we believe
that Tac-based protocols produce better quality of
life and fewer adverse eﬀects when compared with
CsA (29–31). There is only a limited amount of
information about the impact of other new immu-
nosuppressives on patients life quality. However, it
is believed that their use diminishes the side-eﬀects
(28).
Our aim was to explore which factors contribute
to the severity of stress from adverse eﬀects. The
mean total score for stress is relatively low (8.03 of
64) and only gender and education have a signi-
ﬁcant inﬂuence on it. Gender diﬀerences unfavour-
able for females are expected and the female
population in general reports more stress and a
lower quality of life (17, 19–22). Some previous
ﬁndings indicate that quality of life after trans-
plantation is negatively related to total stress but
positively related to coping (3, 26). We expect
people with higher education to use more eﬃcient
coping strategies, which decrease their stress.
However, this statement needs further evaluation.
From the patient’s perspective the most stressful
non-infectious non-oncological adverse eﬀects of
immunosuppression are pain, weakness, cosmetic
changes and psychological symptoms. The stress
from adverse eﬀects is higher in women and less-
educated patients. The type of immunosuppressive
regimen does not seem to inﬂuence the overall
score of stress, but the use of new drugs exhibits
less stress in some symptoms. More research
should be performed in this ﬁeld to identify the
best-balanced protocols with minimum of adverse
eﬀects. Such eﬀorts can identify patients at risk of
severe adverse eﬀects. This could help to decrease
their stress and thus improve quality of life for
kidney transplant recipients. Diminished stress
from adverse eﬀects can contribute to reduction
of their non-compliance and thus can help to
prevent graft damage because of late acute rejec-
tion episodes, which will lead to prolonged graft
and patient survival.
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